{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:18:41Z","timestamp":1775765921392,"version":"3.50.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71573059"],"award-info":[{"award-number":["71573059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40261-016-0486-8","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T08:36:11Z","timestamp":1481099771000},"page":"233-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China"],"prefix":"10.1007","volume":"37","author":[{"given":"Keng","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixia","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shudong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,7]]},"reference":[{"key":"486_CR1","unstructured":"World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis b infection. Available from: http:\/\/www.who.int\/hiv\/pub\/hepatitis\/hepatitis-b-guidelines\/en\/ Accessed Jun 2016."},{"issue":"12","key":"486_CR2","first-page":"888","volume":"23","author":"JL Hou","year":"2015","unstructured":"Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Hou JL, Lai W. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Chin J Hepatol. 2015;23(12):888\u2013905.","journal-title":"Chin J Hepatol."},{"issue":"5 Suppl","key":"486_CR3","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","volume":"49","author":"CJ Chen","year":"2009","unstructured":"Chen CJ, Yang HI, Iloeje UH, REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72\u201384.","journal-title":"Hepatology"},{"issue":"1","key":"486_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology."},{"issue":"1","key":"486_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int."},{"issue":"2","key":"486_CR6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11684-014-0331-5","volume":"8","author":"R Yu","year":"2014","unstructured":"Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med. 2014;8(2):135\u201344.","journal-title":"Front Med."},{"issue":"8","key":"486_CR7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","volume":"5","author":"EB Keeffe","year":"2007","unstructured":"Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5(8):890\u20137.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"25","key":"486_CR8","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576\u201388.","journal-title":"N Engl J Med."},{"key":"486_CR9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1743-422X-8-444","volume":"8","author":"H Lu","year":"2011","unstructured":"Lu H, da Geng Y, Shen F, et al. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. Virol J. 2011;8:444.","journal-title":"Virol J."},{"issue":"1","key":"486_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","volume":"51","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51(1):11\u201320.","journal-title":"J Hepatol."},{"issue":"4","key":"486_CR11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/hep.26885","volume":"59","author":"J Sun","year":"2014","unstructured":"Sun J, Xie Q, Tan D, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283\u201392.","journal-title":"Hepatology."},{"issue":"4","key":"486_CR12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jgh.12835","volume":"30","author":"X Liang","year":"2015","unstructured":"Liang X, Cheng J, Sun Y, et al. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol. 2015;30(4):748\u201355.","journal-title":"J Gastroenterol Hepatol."},{"issue":"2","key":"486_CR13","first-page":"98","volume":"20","author":"XJ Ma","year":"2012","unstructured":"Ma XJ, Chen XP, Chen XF, et al. Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients. Chin J Hepatol. 2012;20(2):98\u2013102.","journal-title":"Chin J Hepatol."},{"issue":"3","key":"486_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40261-015-0273-y","volume":"35","author":"C Zhang","year":"2015","unstructured":"Zhang C, Ke W, Gao Y, et al. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig. 2015;35(3):197\u2013209.","journal-title":"Clin Drug Investig."},{"key":"486_CR15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/DDDT.S98200","volume":"10","author":"C Zhang","year":"2016","unstructured":"Zhang C, Ke W, Liu L, et al. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. Drug Des Devel Ther. 2016;10:897\u2013910.","journal-title":"Drug Des Devel Ther."},{"issue":"6","key":"486_CR16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s12072-016-9741-6","volume":"10","author":"W Ke","year":"2016","unstructured":"Ke W, Zhang C, Liu L, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int. 2016;10(6):924\u201336.","journal-title":"Hepatol Int."},{"issue":"5","key":"486_CR17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4733.2010.00733.x","volume":"13","author":"B Wu","year":"2010","unstructured":"Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13(5):592\u2013600.","journal-title":"Value Health."},{"issue":"2","key":"486_CR18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cgh.2014.06.022","volume":"13","author":"AO Lo","year":"2015","unstructured":"Lo AO, Wong VW, Wong GL, et al. Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. Clin Gastroenterol Hepatol. 2015;13(2):377\u2013385e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"486_CR19","first-page":"46","volume":"10","author":"G Wu","year":"2002","unstructured":"Wu G, Zhou W, Zhao Y, et al. Study on the natural history of chronic hepatitis B. Chin J Hepatol. 2002;10(1):46\u20138.","journal-title":"Chin J Hepatol."},{"key":"486_CR20","first-page":"437","volume":"6","author":"H Huang","year":"2007","unstructured":"Huang H, Zhu CW, Yu XF, et al. The development of cirrhosis in Chinese patients with chronic hepaitits B. Chin Hepatol. 2007;6:437\u201340.","journal-title":"Chin Hepatol."},{"issue":"12","key":"486_CR21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1046\/j.1440-1746.2003.03187.x","volume":"18","author":"B Xu","year":"2003","unstructured":"Xu B, Hu DC, Rosenberg DM, et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol. 2003;18(12):1345\u201352.","journal-title":"J Gastroenterol Hepatol."},{"key":"486_CR22","unstructured":"Tabulation on the 2010 Population Census of the People\u2019s Republic of China. Available from: http:\/\/www.stats.gov.cn\/tjsj\/pcsj\/rkpc\/6rp\/indexch.htm . Accessed Sep 2015."},{"issue":"1","key":"486_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12072-007-5001-0","volume":"1","author":"YC Chen","year":"2007","unstructured":"Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267\u201373.","journal-title":"Hepatol Int."},{"issue":"5","key":"486_CR24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00004836-200205000-00018","volume":"34","author":"AY Hui","year":"2002","unstructured":"Hui AY, Chan HL, Leung NW, et al. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34(5):569\u201372.","journal-title":"J Clin Gastroenterol."},{"issue":"12","key":"486_CR25","first-page":"2157","volume":"125","author":"SB Wang","year":"2012","unstructured":"Wang SB, Wang JH, Chen J, et al. Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients. Chin Med (Engl). 2012;125(12):2157\u201362.","journal-title":"Chin Med (Engl)."},{"issue":"3","key":"486_CR26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/lt.20097","volume":"10","author":"CM Lo","year":"2004","unstructured":"Lo CM, Fan ST, Liu CL, et al. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2004;10(3):440\u20137.","journal-title":"Liver Transpl."},{"issue":"11","key":"486_CR27","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1245\/s10434-013-3023-5","volume":"20","author":"TJ Wu","year":"2013","unstructured":"Wu TJ, Chan KM, Chou HS, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol. 2013;20(11):3582\u201390.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"486_CR28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2169\/internalmedicine.51.7329","volume":"51","author":"M Ha","year":"2012","unstructured":"Ha M, Zhang G, Diao S, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med. 2012;51(12):1509\u201315.","journal-title":"Intern Med."},{"issue":"1","key":"486_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3350\/cmh.2013.19.1.29","volume":"19","author":"MS Park","year":"2013","unstructured":"Park MS, Kim BK, Kim KS, et al. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. Clin Mol Hepatol. 2013;19(1):29\u201335.","journal-title":"Clin Mol Hepatol."},{"issue":"12","key":"486_CR30","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1128\/AAC.01742-13","volume":"57","author":"YB Lee","year":"2013","unstructured":"Lee YB, Lee JH, Choi WM, et al. Efficacy of adefovir-based combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57(12):6325\u201332.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"486_CR31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MCG.0000000000000066","volume":"48","author":"SH Kang","year":"2014","unstructured":"Kang SH, Yim HJ, Kim HR, et al. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B. J Clin Gastroenterol. 2014;48(10):889\u201395.","journal-title":"J Clin Gastroenterol."},{"issue":"1","key":"486_CR32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12072-013-9488-2","volume":"8","author":"JD Jia","year":"2014","unstructured":"Jia JD, Hou JL, Yin YK, et al. Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatol Int. 2014;8(1):72\u201382.","journal-title":"Hepatol Int."},{"issue":"2","key":"486_CR33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47(2):447\u201354.","journal-title":"Hepatology."},{"issue":"2","key":"486_CR34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486\u201395.","journal-title":"Gastroenterology."},{"issue":"4","key":"486_CR35","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20(4):e37\u201346.","journal-title":"J Viral Hepat."},{"issue":"23","key":"486_CR36","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442\u201355.","journal-title":"N Engl J Med."},{"issue":"2","key":"486_CR37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jvh.12313","volume":"22","author":"JL Hou","year":"2015","unstructured":"Hou JL, Gao ZL, Xie Q, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat. 2015;22(2):85\u201393.","journal-title":"J Viral Hepat."},{"issue":"1","key":"486_CR38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1478-3231.2011.02641.x","volume":"32","author":"Z Minde","year":"2012","unstructured":"Minde Z, Yimin M, Guangbi Y, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int. 2012;32(1):137\u201346.","journal-title":"Liver Int."},{"issue":"3","key":"486_CR39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48(3):750\u20138.","journal-title":"Hepatology."},{"issue":"10","key":"486_CR40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001\u201310.","journal-title":"N Engl J Med."},{"issue":"12","key":"486_CR41","first-page":"881","volume":"17","author":"GBRH Yao","year":"2009","unstructured":"Yao GBRH, Xu DZ, Zhou XQ, et al. Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatits B patients. Chin J Hepatol. 2009;17(12):881\u20136.","journal-title":"Chin J Hepatol."},{"issue":"7","key":"486_CR42","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","volume":"106","author":"MF Yuen","year":"2011","unstructured":"Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106(7):1264\u201371.","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"486_CR43","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503\u201314.","journal-title":"Hepatology."},{"issue":"1","key":"486_CR44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","volume":"140","author":"EJ Heathcote","year":"2011","unstructured":"Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140(1):132\u201343.","journal-title":"Gastroenterology."},{"issue":"5","key":"486_CR45","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","volume":"60","author":"M Buti","year":"2015","unstructured":"Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457\u201364.","journal-title":"Dig Dis Sci."},{"key":"486_CR46","doi-asserted-by":"crossref","first-page":"313A","DOI":"10.1002\/hep.27486","volume":"60","author":"P Marcellin","year":"2014","unstructured":"Marcellin P, Gane E, Flisiak R, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis b infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology. 2014;60:313A\u20134A.","journal-title":"Hepatology."},{"issue":"2","key":"486_CR47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","volume":"59","author":"KM Kitrinos","year":"2014","unstructured":"Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434\u201342.","journal-title":"Hepatology."},{"issue":"2","key":"486_CR48","first-page":"82","volume":"28","author":"J Wang","year":"2014","unstructured":"Wang J, Shi JP, Zhu MF, et al. The efficacy and safety comparation between nucleoside (acid) analogue initial combination and monotherapy in the treatment of chronic hepatitis B for 144 weeks. Chin J Exp Clin Virol. 2014;28(2):82\u20134.","journal-title":"Chin J Exp Clin Virol."},{"issue":"3","key":"486_CR49","first-page":"181","volume":"22","author":"YH Liu","year":"2014","unstructured":"Liu YH, Liu L, Peng D, et al. Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients. Chin J Hepatol. 2014;22(3):181\u20134.","journal-title":"Chin J Hepatol."},{"issue":"2","key":"486_CR50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1665-2681(19)30779-3","volume":"14","author":"H Jia","year":"2015","unstructured":"Jia H, Ding F, Chen J, et al. LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV. Ann Hepatol. 2015;14(2):175\u201380.","journal-title":"Ann Hepatol."},{"issue":"11","key":"486_CR51","first-page":"21062","volume":"8","author":"X Li","year":"2015","unstructured":"Li X, Jie Y, You X, et al. Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy. Int J Clin Exp Med. 2015;8(11):21062\u201370.","journal-title":"Int J Clin Exp Med."},{"key":"486_CR52","first-page":"401","volume":"34","author":"YM Jiang","year":"2014","unstructured":"Jiang YM, Liang JC, Chen XX, Gong L, Bao J. Effective analysis of using entecavir in combination with adefovir dipivoxil for a 48-week of chronic hepatitis B patients with lamivudine-resistance. Int J Dig Dis. 2014;34:401\u20135.","journal-title":"Int J Dig Dis."},{"issue":"1","key":"486_CR53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000353851","volume":"57","author":"SY Seo","year":"2014","unstructured":"Seo SY, Kim IH, Sohn JY, et al. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. Intervirology. 2014;57(1):8\u201316.","journal-title":"Intervirology."},{"issue":"5","key":"486_CR54","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s10620-011-1988-0","volume":"57","author":"JW Jeon","year":"2012","unstructured":"Jeon JW, Shin HP, Lee JI, et al. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci. 2012;57(5):1358\u201365.","journal-title":"Dig Dis Sci."},{"issue":"3","key":"486_CR55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12072-007-9009-2","volume":"1","author":"G Yao","year":"2007","unstructured":"Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1(3):365\u201372.","journal-title":"Hepatol Int."},{"issue":"6","key":"486_CR56","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743\u201351.","journal-title":"Gastroenterology."},{"issue":"3","key":"486_CR57","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","volume":"143","author":"AS Lok","year":"2012","unstructured":"Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 2012;143(3):619\u2013628e1.","journal-title":"Gastroenterology"},{"issue":"10","key":"486_CR58","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011\u201320.","journal-title":"N Engl J Med."},{"issue":"2","key":"486_CR59","first-page":"88","volume":"19","author":"JH Yu","year":"2011","unstructured":"Yu JH, Shi JP, Wu J, et al. Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients. Chin J Hepatol. 2011;19(2):88\u201392.","journal-title":"Chin J Hepatol."},{"issue":"3","key":"486_CR60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12072-014-9549-1","volume":"8","author":"YY Dan","year":"2014","unstructured":"Dan YY, Wong JB, Hamid SS, et al. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatol Int. 2014;8(3):382\u201394.","journal-title":"Hepatol Int."},{"issue":"6","key":"486_CR61","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jval.2012.06.005","volume":"15","author":"J He","year":"2012","unstructured":"He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health. 2012;15(6):894\u2013906.","journal-title":"Value Health."},{"issue":"1","key":"486_CR62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65\u201373.","journal-title":"JAMA."},{"issue":"3","key":"486_CR63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678\u201386.","journal-title":"Gastroenterology."},{"issue":"6","key":"486_CR64","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","volume":"37","author":"H Mommeja-Marin","year":"2003","unstructured":"Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37(6):1309\u201319.","journal-title":"Hepatology."},{"key":"486_CR65","unstructured":"Chen L. A cost-effectiveness study on Avarbose to treat type 2 diabetes. Available from: http:\/\/d.wanfangdata.com.cn\/Thesis\/D446438 . Accessed Nov 2015."},{"key":"486_CR66","first-page":"5","volume":"5","author":"Pharmacoeconomics Committee of Chinese Pharmaceutical Association","year":"2010","unstructured":"Pharmacoeconomics Committee of Chinese Pharmaceutical Association. China guidelines for pharmacoeconomic evaluations. Chin J Pham Econ. 2010;5:5\u201343.","journal-title":"Chin J Pham Econ."},{"issue":"2","key":"486_CR67","first-page":"103","volume":"11","author":"GB Yao","year":"2003","unstructured":"Yao GB, Cui ZY, Yao JL, et al. Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study. Chin J Hepatol. 2003;11(2):103\u20138.","journal-title":"Chin J Hepatol."},{"key":"486_CR68","first-page":"100","volume":"33","author":"HY Wang","year":"2014","unstructured":"Wang HY, Guo RC. Comparative study on the domestic and imported entecavir. J Pharm Res. 2014;33:100\u20132.","journal-title":"J Pharm Res."},{"key":"486_CR69","first-page":"3386","volume":"37","author":"KJ Li","year":"2010","unstructured":"Li KJ, Lou XZ, Xia H, et al. A clinical study of home-made adefovir dipivoxil in the 48-week treatment of patients with HBeAg-positive chronic hepatitis B. Modern Prev Med. 2010;37:3386\u20137.","journal-title":"Modern Prev Med."},{"key":"486_CR70","unstructured":"The price of Chinese medicine. Available from: http:\/\/www.zgyyjgw.com\/front\/cn\/retailPrice . Accessed Jun 2016."},{"key":"486_CR71","unstructured":"National Bureau of Staristics of China. Available from: http:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01 . Accessed Sep 2015."},{"issue":"Suppl. 3","key":"486_CR72","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1111\/j.1524-4733.2009.00636.x","volume":"12","author":"M Hu","year":"2009","unstructured":"Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health. 2009;12(Suppl. 3):S89\u201392.","journal-title":"Value Health."},{"key":"486_CR73","unstructured":"Gao Q. Economic analysis for liver and renal transplant in a transplant center. Available from: http:\/\/d.wanfangdata.com.cn\/Thesis\/Y1326546 . Accessed Jun 2016."},{"issue":"3","key":"486_CR74","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527\u201338.","journal-title":"Value Health."},{"issue":"6","key":"486_CR75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jval.2015.05.007","volume":"18","author":"SL Bermingham","year":"2015","unstructured":"Bermingham SL, Hughes R, Fenu E, et al. Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom. Value Health. 2015;18(6):800\u20139.","journal-title":"Value Health."},{"issue":"6","key":"486_CR76","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","volume":"60","author":"FS Wang","year":"2014","unstructured":"Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099\u2013108.","journal-title":"Hepatology."},{"issue":"1","key":"486_CR77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2010.11.002","volume":"21","author":"JG Chen","year":"2011","unstructured":"Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21(1):59\u201369.","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"486_CR78","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jvh.12482","volume":"23","author":"S Zhang","year":"2016","unstructured":"Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat. 2016;23(3):202\u201310.","journal-title":"J Viral Hepat."},{"issue":"2","key":"486_CR79","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1751-2980.2009.00375.x","volume":"10","author":"GB Yao","year":"2009","unstructured":"Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10(2):131\u20137.","journal-title":"J Dig Dis."},{"issue":"1","key":"486_CR80","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/jhep.2002.33894","volume":"36","author":"GV Papatheodoridis","year":"2002","unstructured":"Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology. 2002;36(1):219\u201326.","journal-title":"Hepatology."},{"issue":"4","key":"486_CR81","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.1840400418","volume":"40","author":"V Marco Di","year":"2004","unstructured":"Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883\u201391.","journal-title":"Hepatology."},{"issue":"2","key":"486_CR82","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jhep.2004.10.006","volume":"42","author":"M Rizzetto","year":"2005","unstructured":"Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42(2):173\u20139.","journal-title":"J Hepatol."},{"issue":"4","key":"486_CR83","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","volume":"12","author":"R Gish","year":"2012","unstructured":"Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12(4):341\u201353.","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"486_CR84","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1524-4733.2010.00782.x","volume":"13","author":"H Dakin","year":"2010","unstructured":"Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13(8):922\u201333.","journal-title":"Value Health."},{"issue":"4","key":"486_CR85","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2009.04.013","volume":"51","author":"M Buti","year":"2009","unstructured":"Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51(4):640\u20136.","journal-title":"J Hepatol."},{"issue":"32","key":"486_CR86","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.3748\/wjg.v21.i32.9588","volume":"21","author":"Q Qiu","year":"2015","unstructured":"Qiu Q, Duan XW, Li Y, et al. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence. World J Gastroenterol. 2015;21(32):9588\u201397.","journal-title":"World J Gastroenterol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0486-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0486-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0486-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T05:08:55Z","timestamp":1568610535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0486-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,7]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0486-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,7]]}}}